Evidence map›Paper›PMID 34784657›Full record

ArticleESC heart failure2022

The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial.

Justin A Ezekowitz, Wendimagegn Alemayehu, Sarah Rathwell, Andrew D Grant, Mona Fiuzat, David J Whellan, Tariq Ahmad, Kirkwood Adams, Ileana L Piña, Lawton S Cooper and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.ORCID 0000-0002-2724-4086
Wendimagegn AlemayehuCanadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.ORCID 0000-0002-8549-7962
Sarah RathwellWomen and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada.ORCID 0000-0003-3176-994X
Andrew D GrantDepartment of Cardiac Sciences, Cumming School of Medicine, University of Calgary, and the Libin Institute of Cardiovascular Research, Calgary, AB, Canada.
Mona FiuzatDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-6863-5537
David J WhellanDepartment of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-6287-8690
Tariq AhmadSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
Kirkwood AdamsDivision of Cardiology, University of North Carolina, Chapel Hill, NC, USA.
Ileana L PiñaSchool of Medicine, Wayne State University, Detroit, MI, USA.ORCID 0000-0002-4986-7129
Lawton S CooperNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9704-8777
James L JanuzziMassachusetts General Hospital Harvard Medical School, and Baim Institute for Clinical Research, Boston, MA, USA.ORCID 0000-0002-8338-1798
Eric S LeiferNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-6888-8307
Daniel MarkDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-6340-8087
Christopher M O'ConnorInova Heart and Vascular Institute, Falls Church, VA, USA.
G Michael FelkerDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

aimsN-terminal pro-b-type natriuretic peptide (NT-proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesized that these factors may influence the achievement of NT-proBNP targets and clinical outcomes.

methodsA total of 894 patients with heart failure with reduced ejection fraction were enrolled in The Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment trial. NT-proBNP was analysed every 3 months.

resultsForty per cent of patients had AF, the median estimated glomerular filtration rate (eGFR) was 59 mL/min/1.73 m

conclusionsPatients with AF, a lower BMI, or worse renal function are less likely to achieve a lower or target NT-proBNP. Clinicians should be aware of these factors both when interpreting NT-proBNP levels and making therapeutic decisions about heart failure therapies.

Indexed as

Atrial FibrillationHeart FailureHumansNatriuretic Peptide, BrainPeptide FragmentsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Atrial fibrillationClinical trialHeart failureNatriuretic peptidesObesity

Identifiers

PMID34784657
PMCPMC8787989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.